Literature DB >> 18173964

Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers.

Anthony L McCall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18173964     DOI： 10.1007/s11892-007-0054-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  12 in total

1.  Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.

Authors:  Kishore M Gadde; David B Allison
Journal:  Circulation       Date:  2006-08-29       Impact factor: 29.690

2.  Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies.

Authors:  Roberto Vettor; Roberto Serra; Roberto Fabris; Claudio Pagano; Giovanni Federspil
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

3.  A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.

Authors:  C Berne
Journal:  Diabet Med       Date:  2005-05       Impact factor: 4.359

4.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

5.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.

Authors:  Jaana Lindström; Pirjo Ilanne-Parikka; Markku Peltonen; Sirkka Aunola; Johan G Eriksson; Katri Hemiö; Helena Hämäläinen; Pirjo Härkönen; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Anne Louheranta; Marjo Mannelin; Merja Paturi; Jouko Sundvall; Timo T Valle; Matti Uusitupa; Jaakko Tuomilehto
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

6.  Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

Authors:  James D Otvos; Dorothea Collins; David S Freedman; Irina Shalaurova; Ernst J Schaefer; Judith R McNamara; Hanna E Bloomfield; Sander J Robins
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

7.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

10.  A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.

Authors:  Steven J McNulty; Ehud Ur; Gareth Williams
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.